unresectable locally advanced pancreatic cancer
Conditions
Interventions
(1)Concurrent radiotherapy is delivered in 28 fractions (a total dose of 50.4Gy). (2)Gemcitabine+Nab-Paclitaxel is intravenously administered on day 1,8 and 15 every 4 weeks.
Sponsors
Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1)pancreatic cancer (2)no distant metastasis (3)unresectable defined by NCCN guideline (4)age 20-75 (5)Performance Status:0-1(ECOG) (6)initial treatment (7)Radiotherapist determines that all of the primary tumor and lymph node metastasis is possible to be included in the radiation field of 10cm X 10cm (8)biliary drainage for obstructive jaundice (9)no invasion of digestive tract (10)no other organ cancer (11)adequate oral intake (12)Life expectancy more than 3 months (13)adequate organ function (bone marrow, liver, kidney etc) (14)written informed consent
Exclusion criteria
Exclusion criteria: (1)other distant metastasis (2)allergy of gemcitabine or nab-paclitaxel (3)invasion of digestive tract (4)severe drug allergy (5)active infection (6)severe heart disease (7)severe complications(bowel obstruction, lung fibrosis, interstitial pneumonia, diabetes, renal failure, liver cirrhosis) (8)active synchronous cancer (9)peripheral neuropathy (10)uncontrollable ascites or pleural effusion (11)active gastrointestinal bleeding (12)severe diarrhea (13)mental disorder (14)pregnancy (15)no informed consent (16)inappropriate case (17)pulmonary fibrosis, interstitial pneumonia (18)history of abdominal irradiation (19)uncontrollable carcinomatous pain (20)Lung in the pulmonary field
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| incidence of dose limiting toxicity (within 2 courses) | — |
Countries
Japan
Contacts
Public ContactTsutomu Fujii
Nagoya University Graduate School of Medicine Department of Gastroenterological Surgery (Surgery II)
Outcome results
None listed